Identification of Genetic Variants in Exon 4 of TP53 in Lung Carcinoma and in Silico Prediction of Their Significance

Overview

Journal Indian J Clin Biochem

Specialty Biochemistry

Date 2024 Apr 5

PMID 38577139

Authors

Rajendra Prasad

Kirti Sharma

Karanpreet Bhutani

Suvarna Prasad

Sunita Manhas

Jai Kishan

Affiliations

Soon will be listed here.

Abstract

Lung cancer is a severe and the leading cause of cancer related deaths in men and women all over the world. Tumor suppressor protein (TP53) encoded by the TP53 gene which plays a pivotal role in various cellular tumor suppression processes viz cell cycle arrest and apoptosis. Henceforth, the present study was aimed to TP53 exon4 variants from lung carcinoma. Histopathologic and clinically proven 20 patients of lung cancer were enrolled in this study the average age of patients was 45 ± 8 years which categorized as early onset of lung cancer. Genomic DNA was isolated from the blood specimen of patients. Extracted DNA was subjected to PCR amplification for exon 4 of TP53 using appropriate primers and subsequently amplified products were applied to nucleotide alterations via using the DNA sanger sequencing. The genetic analysis documented five variants in exon4 of TP53 which include viz. 4 substitutions [c.215 > C at codon 72, C. 358-359AA > GG at codon 120] were highly prevalent, occurring in 63% and 25% frequency in patients. Other two variants viz. C. 358 A > C at codon 120, C. 365T > G at codon 122 were present at frequency of 15% whilst one deletion variant [152 del C] was found with 5% frequency. Furthermore, alterations on codon 72, 120,122 and 51 were characterized as possibly damaging by Poly Phen-2 and decreased stability using stability bioinformatic tool. Taken together all these findings infer that TP53 gene involved in modulation and susceptibility to lung cancer.

References

Huang J, Chen M, Chen D, Gao X, Zhu S, Huang H . A Peptide Encoded by a Putative lncRNA HOXB-AS3 Suppresses Colon Cancer Growth. Mol Cell. 2017; 68(1):171-184.e6. DOI: 10.1016/j.molcel.2017.09.015. View

de Andrade K, Mirabello L, Stewart D, Karlins E, Koster R, Wang M . Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history. Hum Mutat. 2017; 38(12):1723-1730. PMC: 6858060. DOI: 10.1002/humu.23320. View

. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View

Ingaramo M, Sanchez J, Dekanty A . Regulation and function of p53: A perspective from Drosophila studies. Mech Dev. 2018; 154:82-90. DOI: 10.1016/j.mod.2018.05.007. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R . Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer. Mutagenesis. 2012; 27(2):211-8. DOI: 10.1093/mutage/ger067. View

Yue X, Zhao Y, Xu Y, Zheng M, Feng Z, Hu W . Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy. J Mol Biol. 2017; 429(11):1595-1606. PMC: 5663274. DOI: 10.1016/j.jmb.2017.03.030. View

Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J . TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. Hum Mutat. 2016; 37(9):865-76. DOI: 10.1002/humu.23035. View

Ma X, Le Teuff G, Lacas B, Tsao M, Graziano S, Pignon J . Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. J Thorac Oncol. 2016; 11(6):850-61. DOI: 10.1016/j.jtho.2016.02.002. View

10.

Mony J, Schuchert M . Prognostic Implications of Heterogeneity in Intra-tumoral Immune Composition for Recurrence in Early Stage Lung Cancer. Front Immunol. 2018; 9:2298. PMC: 6196259. DOI: 10.3389/fimmu.2018.02298. View

11.

Pennell N, Arcila M, Gandara D, West H . Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices. Am Soc Clin Oncol Educ Book. 2019; 39:531-542. DOI: 10.1200/EDBK_237863. View

12.

Pim D, Banks L . p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 2003; 108(2):196-9. DOI: 10.1002/ijc.11548. View

13.

Xu F, Lin H, He P, He L, Chen J, Lin L . A -associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma. Oncoimmunology. 2020; 9(1):1731943. PMC: 7051188. DOI: 10.1080/2162402X.2020.1731943. View

14.

Huszno J, Grzybowska E . mutations and SNPs as prognostic and predictive factors in patients with breast cancer. Oncol Lett. 2018; 16(1):34-40. PMC: 6006469. DOI: 10.3892/ol.2018.8627. View

15.

Prasad R, Panchal S, Rani I, Parashar G, Kishan J, Bhatnagar M . Atypical Case of Highly Mutated h-TERT Promoter in Germline Genome from Buccal Mucosa Cancer. Indian J Clin Biochem. 2023; 38(3):400-404. PMC: 10205942. DOI: 10.1007/s12291-021-01006-8. View

16.

Jovanovic K, Escure G, Demonchy J, Willaume A, Van de Wyngaert Z, Farhat M . Deregulation and Targeting of TP53 Pathway in Multiple Myeloma. Front Oncol. 2019; 8:665. PMC: 6333636. DOI: 10.3389/fonc.2018.00665. View

17.

Faria M, Neves Filho E, Alves M, Burbano R, Moraes Filho M, Rabenhorst S . TP53 mutations in astrocytic gliomas: an association with histological grade, TP53 codon 72 polymorphism and p53 expression. APMIS. 2012; 120(11):882-9. DOI: 10.1111/j.1600-0463.2012.02918.x. View

18.

Bougeard G, Renaux-Petel M, Flaman J, Charbonnier C, Fermey P, Belotti M . Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol. 2015; 33(21):2345-52. DOI: 10.1200/JCO.2014.59.5728. View

19.

Mogi A, Kuwano H . TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol. 2011; 2011:583929. PMC: 3035360. DOI: 10.1155/2011/583929. View

20.

Bykov V, Eriksson S, Bianchi J, Wiman K . Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2017; 18(2):89-102. DOI: 10.1038/nrc.2017.109. View